Cart
sales@molnova.com
Evixapodlin
CAS No. 2374856-75-2
Evixapodlin( —— )
Catalog No. M34846 CAS No. 2374856-75-2
Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 406 | In Stock |
|
| 5MG | 264 | In Stock |
|
| 10MG | 424 | In Stock |
|
| 25MG | 748 | In Stock |
|
| 50MG | 986 | In Stock |
|
| 100MG | 1330 | In Stock |
|
| 200MG | 1795 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEvixapodlin
-
NoteResearch use only, not for human use.
-
Brief DescriptionEvixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.
-
DescriptionEvixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions.
-
In Vitro——
-
In VivoAnimal Model:Female C57BL/6 mice injected with MC38 tumor cells Dosage:10 mg/kg, 25 mg/kg, and 50 mg/kg Administration:Intraperitoneal injection, daily, for 6 days Result:Showed greater than 90% TO on the tumors and inhibited tumor growth in vivo.
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1 | Antiviral | HBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2374856-75-2
-
Formula Weight691.61
-
Molecular FormulaC34H36Cl2N8O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (72.30 mM; Ultrasonic )
-
SMILESCOc1nc(cnc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1cnc(CNC[C@@H]2CCC(=O)N2)c(OC)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Evangelos Aktoudianakis, et al. Pd-1/pd-l1 inhibitors. WO2019160882A1.
molnova catalog
related products
-
INCB086550
INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.
-
Sintilimab
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).
-
Avelumab
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
